Veranex’s Health Economic Model Demonstrates the Potential Cost-Savings from the French Payer Perspective of Using the EXENT® GAM Assay* for Monitoring Patients with Multiple Myeloma

The investigational model considered the use of the EXENT® GAM Assay from the Binding Site, part of Thermo Fisher Scientific. This is a mass spectrometry method that may replace current immunofixation testing and may inform the timing of bone marrow-based minimal residual disease (MRD) testing. With its enhanced sensitivity, the EXENT® GAM Assay was able to detect M-protein in patients otherwise negative by immunofixation, potentially preventing premature MRD testing and its associated costs. In creating this model and the accompanying manuscript, Veranex supported the Binding Site’s efforts to communicate the test’s potential clinical and economic value in France.

Read the article here

*EXENT GAM Assay refers to Immunoglobulin Isotypes (GAM) for the EXENT® Analyser.

EXENT is a registered trademark of The Binding Site Group Limited (Birmingham, UK) in certain countries.

Product availability is subject to country-specific regulatory requirements. Not for use in USA or China.